Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Language
Document Type
Year range
1.
Clin Hematol Int ; 2(4): 173-175, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-1448685
2.
J Zhejiang Univ Sci B ; 21(12): 921-939, 2020.
Article in English | MEDLINE | ID: covidwho-999888

ABSTRACT

The coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a matter of months, this highly contagious novel virus has led to a global outbreak and is still spreading rapidly across continents. In patients with COVID-19, underlying chronic diseases and comorbidities are associated with dismal treatment outcomes. Owing to their immunosuppressive status, patients with hematological malignancies (HMs) are at an increased risk of infection and have a worse prognosis than patients without HMs. Accordingly, intensive attention should be paid to this cohort. In this review, we summarize and analyze specific clinical manifestations for patients with coexisting COVID-19 and HMs. Furthermore, we briefly describe customized management strategies and interventions for this susceptible cohort. This review is intended to guide clinical practice.


Subject(s)
COVID-19/complications , Hematologic Neoplasms/complications , COVID-19/diagnosis , COVID-19/prevention & control , Diagnosis, Differential , Disease Management , Hematologic Neoplasms/diagnosis , Hematologic Neoplasms/virology , Hospitalization , Humans , Immunocompromised Host , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL